Fundraising FoxEQT Life Sciences — 2023 Investments
7 investments dated 2023 · listed companies and verified rows first · show all
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.
BiotechHealthtechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)in
Co-investorsAdBio partnersAndera PartnersAsabys PartnersCanaan PartnersPontifax Venture CapitalV-Bio Ventures+1 more
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenOrbiMedPureos BioventuresSanofi VenturesSunstone Capital+2 more
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter ReitsmainJohn Glasspool(Chief Executive Officer)in
Co-investorsBioGeneration VenturesInkefSound BioventuresYsios CapitalEICUNIIQ+2 more
Lumeon provides an automated care orchestration platform that pulls data from health systems' care processes and existing systems and applies clinical intelligence to coordinate individualized patient care.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechBoston, US
Robbie Hughes(CEO and Founder)in
Board seatRudy Dekeyser· per SEC Form D · $12M raise · filed Aug 2023
Co-investorsEndeavour VisionOptum VenturesTechstarsAmadeus Capital Partners
Immunotherapy company developing NOUS-209 for the prevention of Lynch syndrome-associated cancers.
Co-investors5AM VenturesAndera PartnersAngelini VenturesCDP Venture CapitalIndaco Venture PartnersM Ventures+5 more
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission BiocapitalMitsui Global Investment+7 more
Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsAstellas Venture Management LLCF-Prime CapitalFast Track InitiativeJIC Venture Growth InvestmentsKyoto University Innovation Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.